• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Pioneer Floating Rate

Pioneer Floating Rate

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

    European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

  2. 22nd Century Group Enters Cannabis Space

    22nd Century Group Enters Cannabis Space

  3. Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine

    Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine

  4. Acucela to Present at the BioCentury NewsMakers in the Biotech Industry Conference

    Acucela to Present at the BioCentury NewsMakers in the Biotech Industry Conference

  5. MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal

    MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal

  6. Pioneer Investments Declares Monthly Distributions for Closed-End Funds

    Pioneer Investments Declares Monthly Distributions for Closed-End Funds

  7. Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

    Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

  8. Uranium Energy Corp Reports Positive Preliminary Economic Assessment on Anderson Project in Arizona

    Uranium Energy Corp Reports Positive Preliminary Economic Assessment on Anderson Project in Arizona

  9. Genisphere Closes $2 Million to Accelerate Development of Targeted Drug Delivery Platform

    Genisphere Closes $2 Million to Accelerate Development of Targeted Drug Delivery Platform

  10. Research and Markets: EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023

    Research and Markets: EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.